StreetInsider.com News Articles

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

Featured Interviews Include Aeries Technology (NASDAQ: AERT), Virtuix Holdings (NASDAQ: VTIX), and EmpowerLit; Sponsored Programming Supported by DataVault AI (NASDAQ: DVLT), IGC Pharma (NYSE American: IGC), Medicus Pharma (NASDAQ: MDCX), and NRx Pharmaceuticals (NASDAQ: NRXP)

NEW YORK CITY, NY / ACCESS Newswire / June 20, 2026 / New to The Street, one of the world's most widely distributed business television brands, today announced the broadcast of Show #758 airing at 6:30 PM ET on Bloomberg Television throughout the United States, Latin America, and the Middle East and North Africa (MENA) region.

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

New to The Street broadcasts show #758 TODAY AT 6:30 PM ET on BLOOMBERG TELEVISION ACROSS THE UNITED STATES, LATIN AMERICA, AND MENA

Sat, 20 Jun 2026 13:30:00 -0400

The nationally

Medicus Pharma submits rare pediatric disease designation request for SkinJect

Mon, 15 Jun 2026 07:30:53 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted a Rare Pediatric Disease Designation request to the U.S. Food and Drug Administration for SkinJect, its investigational doxorubicin-containing microneedle array patch, to treat basal cell carcinoma in patients with Gorlin Syndrome.

The submission follows the company's previously announced Orphan Drug Designation application and registrational study design, which remains under FDA review. Medicus developed its Gorlin Syndrome program through engagement with clinical experts and the Gorlin Syndrome Alliance.

Gorlin Syndrome is a rare genetic disorder that affects approximately 1 in 30,000 to 60,000 individuals worldwide. The condition causes patients to develop dozens to thousands of basal cell

Medicus Pharma submits rare pediatric disease designation request for SkinJect

Mon, 15 Jun 2026 07:30:53 -0400

Gorlin Syndrome is a rare genetic disorder that affects approximately 1 in 30,000 to 60,000 individuals worldwide. The condition causes patients to develop dozens to thousands of basal cell

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Mon, 15 Jun 2026 07:30:00 -0400

Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced the submission of a Rare Pediatric Disease Designation (“RPDD”) request to the U.S. Food and Drug Administration (“FDA”) for SkinJect®, the Company’s investigational doxorubicin-containing microneedle array patch (D-MNA), for the treatment of basal cell carcinoma (“BCC”) in patients with Gorlin

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Mon, 15 Jun 2026 07:30:00 -0400

Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Mon, 15 Jun 2026 07:30:00 -0400

Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Mon, 15 Jun 2026 07:30:00 -0400

Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginning in Childhood

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2026 / New to The Street announces its upcoming Saturday broadcast airing across Bloomberg Television in the United States, Latin America, and the Middle East and North Africa (MENA), featuring innovative public companies, entrepreneurs, and industry thought leaders.

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

New to The Street Broadcasting Saturday June 13th 630pm est ACROSS BLOOMBERG TELEVISION IN THE U.S., LATIN AMERICA, AND MENA

Fri, 12 Jun 2026 14:45:00 -0400

Brent Lucas, CEO of Envoy Medical (NASDAQ:COCH), Discusses the Company's Breakthrough Fully Implanted Hearing Device Designed to Deliver 24-Hour Hearing

Leading this week's program is Brent Lucas, Chief Executive Officer of Envoy Medical (NASDAQ:COCH), who discusses the company's groundbreaking fully implanted hearing device technology designed

Medicus Pharma starts genomic endometriosis trial in UAE

Thu, 11 Jun 2026 07:30:23 -0400

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted an Investigational New Drug application to the Department of Health, Abu Dhabi for PRECISION-E2, a Phase 2a clinical trial evaluating Teverelix® in women with endometriosis in the United Arab Emirates.

The study will enroll approximately 84 participants across multiple UAE sites and evaluate three Teverelix treatment regimens using both subcutaneous and intramuscular administration. The trial aims to identify optimal dosing and administration methods for controlled estradiol suppression while maintaining safety.

PRECISION-E2 will leverage participants from the Emirati Genome Program to explore genetic variations that may influence treatment response. The study combines clinical outcomes, hormonal biomarkers, pharmacokinetic